Lupin launches generic drug to treat depression in US

Pharma major Lupin Ltd (Lupin) today announced the launch of generic drug Pristiq (Desvenlafaxine Succinate) to treat depression in the US market.

"We have launched generic Pristiq (Desvenlafaxine Succinate) extended-release tablets, 50 mg and 100 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. This is the AB rated generic equivalent of Wyeth Pharmaceuticals' Pristiq tablets," a company statement said here.

It is indicated for the treatment of major depressive disorder (MDD).

Pristiq tablets had annual US sales of approximately USD 859.9 million.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and holds global leadership position in the anti-TB segment.